Compass Therapeutics (CMPX) Other financing activities (2022 - 2026)

Compass Therapeutics has reported Other financing activities for 3 years, with the latest figure at $3.9 million in Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (changed N/A YoY) and the FY2025 annual result came in at $1.3 million, changed N/A from the prior year.
• Other financing activities grew to $3.9 million in Q1 2026 per CMPX's latest filing, from $21000.0 in the prior quarter.
• Over five years, Other financing activities peaked at $3.9 million in Q1 2026 and troughed at $5000.0 in Q3 2022.
• A 3-year average of $786200.0 and a median of $21000.0 in 2023 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 320.0% in 2023, down 320.0% in 2023.
• Over 3 years, Other financing activities stood at $10000.0 in 2022, then soared by 110.0% to $21000.0 in 2023, then soared by 18252.38% to $3.9 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $3.9 million, $21000.0, and $41000.0 for Q1 2026, Q3 2023, and Q1 2023 respectively.